National

COVID-19 vaccine in 1 month? CSIR pins hope on Sepsivac

NEW DELHI, MAY 2 (IANS) | Publish Date: 5/2/2020 12:08:38 PM IST

India’s top research and development organisation, the Council of Scientific & Industrial Research (CSIR), which is currently testing a “repurposed” vaccine against Covid-19 in a Phase 2 trial, is hoping to seek approval from drug controller for its wider use against the pandemic in as early as 30 days from now, the scientist who is coordinating the effort said on Saturday. CSIR is currently testing Cadila Pharmaceuticals’ “Sepsivac” against COVID-19.

This treatment was developed as a result of a partnership between CSIR and Cadila Pharmaceuticals many years ago. This immunotherapy treatment, which boosts “innate immunity”, was initially approved by Drug Controller General of India (DCGI) for gram negative sepsis which is a disease caused by bacteria.

But the scientists found that the pathological symptoms of this disease and Covid-19 were quite similar. And given the urgency of finding a solution to the rapidly rising Covid-19 cases across the world, the scientists thought of testing the treatment against the current pandemic caused by the SARS-CoV-2 virus.

CSIR got the approval to test “Sepsivac” against Covid-19 in a Phase 2 clinical trial about 10 days ago. The trial is being conducted on 50 patients at AIIMS New Delhi, AIIMS Bhopal, and Post Graduate Institute of Medical Education & Research (PGIMER) Chandigarh.

“We expect the results from this Phase 2 trial within 30-45 days from now. And if the results are encouraging, we will seek approval from the drug controller because of emergency and keep on continuing the Phase 3 trial. That’s how it happens,” Ram Vishwakarma, Director, Integrative Medicine (Council of Scientific & Industrial Research), Jammu, told IANS.

Vishwakarma said that once it applies, the approval from drug controller is expected to come fast as it is an emergency situation.

So if the Phase 2 trial shows that “Sepsivac” is effective against Covid-19, the world may have a vaccine against the disease as early as one month from now, at least for emergency use.

Meanwhile, Vishwakarma informed that CSIR has also got approval for conducting Phase 3 clinical trial of “Sepsivac” against Covid-19.

How does Sepsivac work?

It contains heat-killed mycobacterium w (Mw), an immunomodulator, which is a non-pathogenic mycobacterium. “Normally when you develop a vaccine, you grow the organism and kill it. It is called heat killed. Here we heat killed the bacteria. It is a standard vaccine concept,” Vishwakarma said, adding that the bacterium is produced by fermentation.

“The treatment we are testing against Covid-19 is designed to enhance innate immunity which is very critical. People who are weak in innate immunity will get infection faster,” he said.

He explained that it is a non-specific vaccine which could be used to both cure and protect people. He explained that there are generally three types of vaccines.

“There are therapeutic vaccines, where you give them as a drug for curing. There are prophylactic vaccines, which you give to people to protect them. And there are some which have both the properties, which are called immunomodulators...Sepsivac will be an immunomodulator, which will have protective effect and therapeutic effect both,” he said.

 

Launched on December 3,1990. Nagaland Post is the first and highest circulated newspaper of Nagaland state. Nagaland Post is also the first newspaper in Nagaland to be published in multi-colour.

Desk:+91-3862-248 489, e-mail: npdesk@gmail.com Fax: +91-3862-248 500
Advt.:+91-3862-248 267, e-mail:npostadvt@gmail.com

QUICK LINKS

SUNDAY POST

Join us on

© Nagaland Post 2018. All Rights are Reserved
Designed by : 4C Plus